These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23364275)

  • 1. Correlation between Ki67 and breast cancer prognosis.
    Kontzoglou K; Palla V; Karaolanis G; Karaiskos I; Alexiou I; Pateras I; Konstantoudakis K; Stamatakos M
    Oncology; 2013; 84(4):219-25. PubMed ID: 23364275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
    J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of apoptotic and proliferative markers in breast cancer.
    Engels CC; Ruberta F; de Kruijf EM; van Pelt GW; Smit VT; Liefers GJ; Matsushima T; Shibayama M; Ishihara H; van de Velde CJ; Kuppen PJ
    Breast Cancer Res Treat; 2013 Nov; 142(2):323-39. PubMed ID: 24194179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
    Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility.
    Ekholm M; Beglerbegovic S; Grabau D; Lövgren K; Malmström P; Hartman L; Fernö M
    Histopathology; 2014 Aug; 65(2):252-60. PubMed ID: 24527721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67 and proliferation in breast cancer.
    Pathmanathan N; Balleine RL
    J Clin Pathol; 2013 Jun; 66(6):512-6. PubMed ID: 23436927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
    de Azambuja E; Cardoso F; de Castro G; Colozza M; Mano MS; Durbecq V; Sotiriou C; Larsimont D; Piccart-Gebhart MJ; Paesmans M
    Br J Cancer; 2007 May; 96(10):1504-13. PubMed ID: 17453008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
    Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
    Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy.
    Selz J; Stevens D; Jouanneau L; Labib A; Le Scodan R
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1123-32. PubMed ID: 22572073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
    Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
    J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential utility of geminin as a predictive biomarker in breast cancer.
    Sundara Rajan S; Hanby AM; Horgan K; Thygesen HH; Speirs V
    Breast Cancer Res Treat; 2014 Jan; 143(1):91-8. PubMed ID: 24292956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?
    Ahlin C; Aaltonen K; Amini RM; Nevanlinna H; Fjällskog ML; Blomqvist C
    Histopathology; 2007 Oct; 51(4):491-8. PubMed ID: 17711446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index.
    Jalava P; Kuopio T; Juntti-Patinen L; Kotkansalo T; Kronqvist P; Collan Y
    Histopathology; 2006 May; 48(6):674-82. PubMed ID: 16681683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of Ki67 in breast cancer: the debate is still open.
    Colozza M; Sidoni A; Piccart-Gebhart M
    Lancet Oncol; 2010 May; 11(5):414-5. PubMed ID: 20434714
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node.
    Tvedskov TF; Bartels A; Jensen MB; Paaschburg B; Kroman N; Balslev E; Brünner N
    APMIS; 2011 Dec; 119(12):844-52. PubMed ID: 22085360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki67 in breast cancer: prognostic and predictive potential.
    Yerushalmi R; Woods R; Ravdin PM; Hayes MM; Gelmon KA
    Lancet Oncol; 2010 Feb; 11(2):174-83. PubMed ID: 20152769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment tumor markers by immunohistochemistry (Ki67, p53 and Bcl-2) on a cohort of patients with cervical cancer in various stages of evolution].
    Stoenescu TM; Ivan LD; Stoenescu N; Azoicăi D
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):485-92. PubMed ID: 21870745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.